1491 completed, 569 unknown, 437 recruiting, 344 terminated. 2010 Phase 2, 873 Phase 3, 701 Phase 1, 95 Not applicable, 41 Phase 4.
Follow Cisplatin: new trials by email Literature Review of Cisplatin trials Research Report on Cisplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| Chemo-embolization for Head and Neck Cancer Cisplatin - SCCHN, Squamous Cell Carcinoma | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2027-05-01 | 2025-04-27 | |
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer Telaglenastat, Radiation treatment, Cisplatin - Advanced Cervical Carcinoma, Cervical Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 42 | 2026-12-31 | 2026-09-03 |
| Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors ISM5939, Cisplatin, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Not yet recruiting | InSilico Medicine Hong Kong Limited | 159 | 2026-12-30 | 2026-07-23 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-10-26 |
| Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. Nivolumab, Gemcitabine, Cisplatin - Advanced Biliary Tract Cancer(BTC) | Phase 2 | Withdrawn | National Health Research Institutes, Taiwan | 2026-12-01 | 2026-07-02 | |
| Intralesional Chemotherapy (IC): Cisplatin + Epinephrine Cisplatin, Epinephrine injection, Laryngeal Biopsy - Laryngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Miami | 20 | 2026-12-01 | 2026-08-26 |
| Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 298 | 2026-12-01 | 2026-10-27 |
| Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM) - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 214 | 2026-12-01 | 2026-10-29 |
| Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies Liposomal Irinotecan Plus Cisplatin - Advanced Solid Malignancies | Phase 1 | Not yet recruiting | National Health Research Institutes, Taiwan | 44 | 2026-12-01 | 2026-11-02 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 80 | 2026-11-30 | 2026-10-13 |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-08 | 2026-11-03 |
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity Belinostat, Cisplatin, Etoposide - Carcinoma, Neuroendocrine, Tumor, Neuroendocrine | Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2026-11-08 | 2026-11-03 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 38 | 2026-11-01 | 2026-07-22 |
Showing 20 of 3414. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (565) · Squamous Cell Carcinoma of Head and Neck (292) · Head and Neck Neoplasms (259) · Lung Neoplasms (242) · Uterine Cervical Neoplasms (185) · Stomach Neoplasms (173) · Esophageal Neoplasms (163) · Nasopharyngeal Carcinoma (131) · Esophageal Squamous Cell Carcinoma (125) · Urinary Bladder Neoplasms (121) · Neoplasms (119) · Small Cell Lung Carcinoma (108) · Neoplasm Metastasis (94) · Ovarian Neoplasms (93) · Breast Neoplasms (92)
National Cancer Institute (NCI) (132) · Sun Yat-sen University (102) · Eli Lilly and Company (84) · Memorial Sloan Kettering Cancer Center (82) · Merck Sharp & Dohme LLC (67) · AstraZeneca (61) · M.D. Anderson Cancer Center (57) · European Organisation for Research and Treatment of Cancer - EORTC (48) · Fudan University (48) · Hoffmann-La Roche (43) · Radiation Therapy Oncology Group (42) · Gynecologic Oncology Group (40) · Dana-Farber Cancer Institute (36) · Bristol-Myers Squibb (35) · Children's Oncology Group (34)
United States (1457) · China (931) · France (385) · Spain (341) · Canada (335) · South Korea (317) · Italy (315) · United Kingdom (307) · Germany (302) · Australia (230) · Japan (226) · Taiwan (226) · Belgium (213) · Poland (188) · Netherlands (181)
David H. Ilson, MD, PhD (13) · Jun Ma, M.D. (10) · Cesare Gridelli, M.D. (8) · Corey J. Langer, MD (8) · David J. Adelstein, MD (7)
PMID 25057165, PMID 29567784, PMID 31150573, PMID 31401903, PMID 33357481, PMID 37139963, PMID 40501401, PMID 21444871, PMID 22551107, PMID 22689675, PMID 24982463, PMID 28837405, PMID 29584545, PMID 29658856, PMID 30213452, PMID 33358660, PMID 37699333, PMID 41343184, PMID 16394300, PMID 16957145, PMID 17960012, PMID 18784101, PMID 19139178, PMID 19465425, PMID 19564532, PMID 20818904, PMID 21840137, PMID 22178121, PMID 22248721, PMID 23228446, PMID 23683550, PMID 23831416, PMID 24662947, PMID 25366678, PMID 25477010, PMID 25624439, PMID 26313683, PMID 27246305, PMID 27465021, PMID 27567280, PMID 27718847, PMID 28742685, PMID 28797458, PMID 29342393, PMID 29924955, PMID 30207593, PMID 30267838, PMID 30548235, PMID 30633128, PMID 30976202
2023 (57), 2018 (32), U10CA180868 (32), U10CA032102 (31), 2016 (28), U10CA027469 (26), U10CA180820 (26), 2015 (24), 2017 (24), 2014 (22), U10CA180886 (22), 2019 (21), U10CA098543 (19), 2009 (17), U10CA031946 (16)